You Searched For "biogen" and got 20 results
Sort By:
1 min read
Biogen jumps 6% ahead of a key FDA decision for its Alzheimer's drug
The second phase 3 trial for Biogen's aducanumab failed to meet its primary and secondary endpoints…
Matthew Fox
2 mins read
Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
JPMorgan estimates the Alzheimer's drug could generate between $6 billion and $10 billion in peak s…
Matthew Fox
3 mins read
An experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
In a late-stage trial, Eli Lilly's experimental Alzheimer's treatment slowed the rate of cognitive …
Yeji Jesse Lee
2 mins read
Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.
Buffett's company established stakes in Merck, AbbVie, and Bristol Myers Squibb in the second half …
Theron Mohamed
1 min read
Biogen plummets 32% after its Alzheimer's therapy fails to win support from FDA advisory committee
The committee voted 8-1 that data from a Biogen study evaluating patients with mild Alzheimer's was…
Matthew Fox
1 min read
Biogen soars 47% after FDA scientists say its Alzheimer's drug's efficacy is 'exceptionally persuasive'
Biogen's drug aducanumab, which was jointly developed with Japan's Eisai, will receive an FDA appro…
Matthew Fox
3 mins read
The top doctor at a $2.7 billion pharma company developing a new depression drug says we may be 'on the cusp' of a new wave of mental-health treatments
Sage Therapeutics is developing an antidepressant that works quickly, with patients only taking the…
Yeji Jesse Lee
4 mins read
Depression treatments haven't changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people.
A new generation of treatments promises to help more people with depression.
Yeji Jesse Lee
2 mins read
A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug
Dr. Aaron Kesselheim said the agency's decision to approve Biogen's new drug "was probably the wors…
Erin Snodgrass
2 mins read
Warren Buffett's Berkshire Hathaway scores $60 million gain on Biogen after FDA approval sends the stock to record high
The famed investor's company saw its Biogen stake soar in value after federal regulators approved t…
Theron Mohamed
1 min read
Microsoft tops the list of most transparent companies for diversity data. Here's how far the top 5 have come - and how they can still improve.
They ranked the companies based on 14 equally weighted metrics that measured how much diversity dat…
Marguerite Ward
3 mins read
The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease
Two Alzheimer's drugs, Biogen's Leqembi and Eli Lilly's donanemab, treat the disease by focusing on…
Yeji Jesse Lee
1 min read
Morgan Stanley double-upgrades Biogen and says the stock can surge another 30%
"While BIIB remains a high-risk/ high-reward stock, we think now is the right time to take the risk…
Carmen Reinicke
4 mins read
The FDA just approved a new Alzheimer's drug that's set to be a blockbuster
The new drug, called Leqembi, slowed the rate of cognitive decline in Alzheimer's patients by 27%.
Yeji Jesse Lee
4 mins read
This Alzheimer’s drug slowed cognitive decline in some patients. Analysts say it could become a blockbuster hit.
Full results of Biogen and Eisai's Alzheimer's study on lecanemab give some credence to a controver…
Yeji Jesse Lee
2 mins read
A medical conference held in late February in Boston may have caused up to 300,000 coronavirus infections, new study finds
By studying the genetic code of cases first linked to the conference, scientists determined it spre…
Connor Perrett
1 min read
Biogen soars 64% after FDA approves first new Alzheimer's drug in 18 years
The FDA approval marks the first treatment cleared by US regulators to decelerate cognitive decline…
Isabelle Lee
3 mins read
A conference held in Boston in late February may be responsible for tens of thousands of coronavirus infections in the US and abroad
"We're not trying to point fingers," Bronwyn MacInnis said. "Some [viral] introductions fizzle out,…
Sarah Al-Arshani
2 mins read
Warren Buffett's Berkshire Hathaway sold its Biogen stake last quarter - and slashed its pharmaceutical bets
The famed investor's company also sold some Chevron and General Motors shares, and boosted its stak…
Theron Mohamed
2 mins read
Why 2022 could be the most crucial year yet for gene editing
These are Insider's biggest healthcare stories for December 21.